Shanghai SciBrunch Therapeutics Co., Ltd.
1 clinical trials · Sponsor
◉ Watch Shanghai SciBrunch Therapeutics Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors (NCT07359066) | Shanghai SciBrunch Therapeutics Co., Ltd. | 2026-01-08 |
Track Shanghai SciBrunch Therapeutics Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.